Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery, Structural Characterization, and Preclinical Evaluation of Monoclonal Antibodies against Xylazine Poisoning.

ACS pharmacology & translational science·2026
Same author

Novel Swine Model of Respiratory Depression Induced by Fentanyl and Heroin Overdose.

Research square·2026
Same author

Impact of morphine dependence and withdrawal on economic demand for fentanyl, cocaine, and methamphetamine in rats.

Drug and alcohol dependence·2025
Same author

Erratum to "Innate immune mechanisms underlying the efficacy of a next-generation nanoparticle-based vaccine against opioid use disorders" [Journal of Controlled Release 388 (2025) 114294].

Journal of controlled release : official journal of the Controlled Release Society·2025
Same author

An antifentanyl monoclonal antibody reverses fentanyl-induced apnea in pigs.

The Journal of pharmacology and experimental therapeutics·2025
Same author

Development of Central Nervous System-Penetrant Apelin Receptor Agonists.

Journal of medicinal chemistry·2025

Related Experiment Video

Updated: May 31, 2026

The 6-hydroxydopamine Rat Model of Parkinson's Disease
08:10

The 6-hydroxydopamine Rat Model of Parkinson's Disease

Published on: October 27, 2021

Prophylactic Active Immunization Protects against Xylazine-Induced Pharmacological Effects in Rats.

Caroline M Kim1, Robert W Seaman1, Courtney Marecki1

  • 1School of Medicine, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle 98195, Washington, United States.

Journal of Medicinal Chemistry
|May 29, 2026
PubMed
Summary

A new xylazine vaccine shows promise in preventing overdose toxicity by blocking the drug

More Related Videos

X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models
12:57

X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models

Published on: December 9, 2022

Induction of Periodontitis via a Combination of Ligature and Lipopolysaccharide Injection in a Rat Model
06:14

Induction of Periodontitis via a Combination of Ligature and Lipopolysaccharide Injection in a Rat Model

Published on: February 17, 2023

Related Experiment Videos

Last Updated: May 31, 2026

The 6-hydroxydopamine Rat Model of Parkinson's Disease
08:10

The 6-hydroxydopamine Rat Model of Parkinson's Disease

Published on: October 27, 2021

X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models
12:57

X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models

Published on: December 9, 2022

Induction of Periodontitis via a Combination of Ligature and Lipopolysaccharide Injection in a Rat Model
06:14

Induction of Periodontitis via a Combination of Ligature and Lipopolysaccharide Injection in a Rat Model

Published on: February 17, 2023

Area of Science:

  • Pharmacology and Toxicology
  • Immunology
  • Drug Discovery

Background:

  • Opioid-related overdoses are increasing, with xylazine (a veterinary tranquilizer) worsening the crisis through polydrug exposure.
  • No FDA-approved treatments currently exist for xylazine-induced overdose toxicity in humans.
  • Xylazine, also known as "tranq" or "tranq dope," is an α2 adrenergic receptor agonist contributing to overdose deaths.

Purpose of the Study:

  • To develop and test the efficacy of novel xylazine-based conjugate vaccines against xylazine-induced overdose toxicity.
  • To investigate the potential of a multivalent vaccine strategy combining xylazine and fentanyl vaccines.

Main Methods:

  • Development and characterization of xylazine-based haptens and their cognate conjugate vaccines.
  • Testing vaccine efficacy against xylazine-induced pharmacological effects in a rat model.
  • Evaluation of a multivalent formulation strategy for combined xylazine and fentanyl vaccine protection.

Main Results:

  • Active immunization with the xylazine vaccine demonstrated protection against xylazine-induced effects in rats.
  • Vaccine efficacy was attributed to limiting xylazine's entry into the brain and mitigating its pharmacological actions.
  • Preliminary evidence suggests a combined xylazine-fentanyl vaccine can protect against drug mixtures.

Conclusions:

  • Novel xylazine-based vaccines offer a potential immunotherapeutic approach to prevent xylazine toxicity.
  • Vaccine strategies may mitigate risks associated with polydrug exposure involving xylazine and synthetic opioids.
  • Further research into immunotherapeutics could address the unmet need for xylazine overdose treatment.